Evidence map›Paper›PMID 26874530›Full record

ReviewCurrent urology reports2016

Prostate Cancer Imaging with Novel PET Tracers.

Liza Lindenberg, Peter Choyke, William Dahut

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current urology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. [Focus on molecular imaging in prostate cancer].Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
    Pooled it
  3. Trial
  4. Prostate Specific Membrane Antigen TargetedThe Journal of urology · 2018
    Trial
  5. Review
  6. Comparison of PSMA-basedAmerican journal of nuclear medicine and molecular imaging · 2023
    Article
  7. Review
  8. Review
  9. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. European journal of nuclear medicine and molecular imaging · 2017
    Article
  15. Article
  16. Early dynamic imaging inEuropean journal of nuclear medicine and molecular imaging · 2017
    Article
  17. Review
  18. FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Liza LindenbergCenter for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. liza.lindenberg@mail.nih.gov.
Peter ChoykeCenter for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. pchoyke@mail.nih.gov.
William DahutCenter for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. dahutw@mail.nih.gov.
Center for Cancer Research · USNational Cancer Institute · US

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Intramural NIH HHS ZIA BC010655
6 · The paper itself

Abstract

Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.

Indexed as

Positron-Emission TomographyAntigens, SurfaceGlutamate Carboxypeptidase IIHumansMaleMultimodal ImagingProstatic NeoplasmsRadiopharmaceuticalsTomography, X-Ray ComputedAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticals11C/18F choline11C acetate18F DCFBC18F DHT18F FACBC18F NaF68Ga PSMA

Identifiers

PMID26874530
PMCPMC6364683
OpenAlexW2325838250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.